UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Alavita Pharmaceuticals Inc. operates as a biotechnology company that developes therapeutics for treatment of damage associated with stroke, heart attacks, and organ transplantation. The company was founded in 2005 and is based in Mountain View, California. Alavita Pharmaceuticals Inc. operates as a subsidiary of Pharmaceutical Product Development, Inc.

Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company within the Annexin A5 area, for the treatment of various cardiovascular diseases. The company's biological drug candidate ANXV - a human recombinant protein, Annexin A5 - is primarily intended for acute treatment of patients with cardiovascular diseases with injuries and inflammation in the blood vessels. In addition, the company has an extensive patent portfolio for the treatment of diseases that arise due to damage and inflammation of the blood vessels. Annexin Pharmaceuticals has established and optimized a cell line for large-scale manufacturing of Annexin A5. The production process is patent-pending. ANXV has the ability to protect and repair the blood vessels and to counteract the inflammation. Thus, ANXV is expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major diseases such as heart attack. ANXV has the potential to become First-In-Class (product with new unique mechanisms of action that is the first of its kind in the market) for several patient groups where there are large unmet medical treatment needs.

ProteoSys AG offers biotechnology research services. It provides solutions for the drug development process focusing on target system discovery, target validation, modes of action, studies of side effects and toxicology. The company was founded by Andr�� Schrattenholz and Helmut Matthies in 2000 and is headquartered in Mainz, Germany.

Jiangsu Target Biomedical Research Institute Co., Ltd., established on 2008-10-28, Business scope includes biotechnology research and development;Technology transfer for R&D products,technical consulting,Technical Services;Instrumentation,equipment,electronic product,Biochemical reagents,Sales of computer accessories and software;Self-operated and agent import and export business of various commodities and technologies,Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export;food business(limit<food business license>Approved scope);food production(limit<food production license>Approved scope);Cosmetic sales;Cosmetic production(limit<Cosmetic Production License>Approved scope).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Part of MOH Holdings Pte Ltd., Singapore Health Services Pte Ltd. is a Singaporean company located in Singapore. The firm provides medical services. Ivy Ng is the CEO, in this role since 2012.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

FANCL Corp. engages in the manufacture and sale of cosmetics and nutritional supplements. It operates through the following segments: Cosmetics, Nutritional Supplements, and Others. The Cosmetics segment deals with manufacture and sale of cosmetics and provides original equipment manufacturer products. The Nutritional Supplements segment handles manufacture and sale of food supplements. The Others segment includes online sales of undergarments, health equipment, and lifestyle products. It also offers germinated brown rice, kale juice, and esthetic business. The company was founded by Kenji Ikemori in April 1980 and is headquartered in Yokohama, Japan.

ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin A1 as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role. Their current focus is on cardiovascular disorders and inflammatory disorders with a large unmet medical need.

MedAnnex Ltd. operates preclinical-stage biotechnology company. It develops approaches to treating autoimmune diseases and other medical conditions. The company was founded by Christopher Barry Wood and Hugh Stephen Griffith in 2009 and is headquartered in Edinburgh, the United Kingdom.

Board of Regents of The University of Oklahoma is a private company headquartered in Norman, OK, with domestic subsidiaries, specializing in radio broadcasting stations.

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of oncology products. The company is currently focusing on developing picoplatin, a new and differentiated platinum-based chemotherapeutic agent that is used in the clinical development for multiple cancer indications, treatment combinations, and by different routes of administration. The company was founded in 1984 and is headquartered in Seattle, WA.